Drug pricing didn’t come up in White House biomedical meeting, NIH director says | CNBC

It was an elephant in the room: Drug pricing has been a key focus of President Donald Trump’s narrative on the drug industry since even before he took office. But in a White House meeting on biomedical research Monday, which included executives from drug companies as well as academic and government health leaders, the topic didn’t come up.

“There’s all kinds of elephants, and the room is crowded with them, I suppose, but that one didn’t get much attention,” Dr. Francis Collins, director of the National Institutes of Health, told CNBC in an interview directly after the meeting.

The group was invited to the Oval Office after the two-hour meeting to share conclusions with the president, Collins said. Trump didn’t participate in the main part of the event, which was attended by Ivanka Trump and Jared Kushner, Health and Human Services Secretary Tom Price, and initially by Vice President Mike Pence.

Read complete article here:

Drug pricing didn’t come up in White House biomedical meeting, NIH director says.